AhmedH, PatelK, GreenwoodDC, et al.Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis. J Rehabil Med, 2020; 52:jrm00063.
2.
AndersonEJ, RouphaelNG, WidgeAT, et al.Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med, 2020; 383:2427–2438.
3.
ArnoldD, MilneA, SammsE, StadonL, MaskellN, and HamiltonF. Are vaccines safe in patients with Long COVID? A prospective observational study. medRxiv, 2021; DOI: 10.1101/2021.03.11.21253225.
4.
ArnoldDT, MilneA, SammsE, StadonL, MaskellNA, and HamiltonFW. Symptoms after COVID-19 vaccination in patients with persistent symptoms after acute infection: a case series. Ann Intern Med, 2021; 174:1334–1336.
5.
CollinsFS. NIH launches new initiative to study “long COVID.” 2021. (https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study-long-covid) (accessed August24, 2021).
6.
DalyM, JonesA, and RobinsonE. Public trust and willingness to vaccinate against COVID-19 in the US from October 14, 2020, to March 29, 2021. JAMA, 2021; 325:2397–2399.
7.
Das AdhikariU, EngG, FarcasanuM, et al.Fecal SARS-CoV-2 RNA is associated with decreased COVID-19 survival. Clin Infect Dis, 2021; DOI: 10.1093/cid/ciab623.
8.
DattaSD, TalwarA, and LeeJT. A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA, 2020; 324:2251–2252.
9.
DiaoB, WangC, WangR, et al.Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. Nat Commun, 2021; 12:2506.
10.
DongE, DuH, and GardnerL. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis, 2020; 20:533–534.
11.
DoykovI, HällqvistJ, GilmourKC, GrandjeanL, MillsK, and HeywoodWE. ‘The long tail of Covid-19’—the detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Res, 2020; 9:1349.
12.
FilesJK, SarkarS, FramTR, et al.Duration of post-COVID-19 symptoms are associated with sustained SARS-CoV-2 specific immune responses. JCI Insight, 2021; DOI: 10.1172/jci.insight.151544.
13.
GreenhalghT, KnightM, A'CourtC, BuxtonM, and HusainL. Management of post-acute covid-19 in primary care. BMJ, 2020; 370:m3026.
14.
HavervallS, RosellA, PhillipsonM, et al.Symptoms and functional impairment assessed 8 months after mild COVID-19 among health care workers. JAMA, 2021; 325:2015–2016.
15.
NabaviN. Long covid: how to define it and how to manage it. BMJ, 2020; 370:m3489.
PuellesVG, LütgehetmannM, LindenmeyerMT, et al.Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med, 2020; 383:590–592.
18.
RaveendranAV, JayadevanR, and SashidharanS. Long COVID: an overview. Diabetes Metab Syndr, 2021; 15:869–875.
19.
RemmelinkM, De MendonçaR, D'HaeneN, et al.Unspecific post-mortem findings despite multiorgan viral spread in COVID-19 patients. Crit Care, 2020; 24:495.
20.
TavazziG, PellegriniC, MaurelliM, et al.Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur J Heart Fail, 2020; 22:911–915.
21.
TroisiJ, VenutoloG, Pujolassos TanyàM, Delli CarriM, LandolfiA, and FasanoA. COVID-19 and the gastrointestinal tract: source of infection or merely a target of the inflammatory process following SARS-CoV-2 infection?. World J Gastroenterol, 2021; 27:1406–1418.
22.
VaughanA. How to stop vaccine hesitancy. New Sci, 2020; 248:12–13.
23.
WuZ, and McGooganJM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: summary of a Report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 2020; DOI: 10.1001/jama.2020.2648.
24.
ZicariS, SessaL, CotugnoN, et al.Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses, 2019; 11:200.